会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • Process for preparing a pharmaceutically active compound (granisetron)
    • 制备药物活性化合物(格拉司琼)的方法
    • US07071209B2
    • 2006-07-04
    • US10508493
    • 2003-03-21
    • Salvador Puig TorresPere Dalmases Barjoan
    • Salvador Puig TorresPere Dalmases Barjoan
    • C07D421/12
    • C07D471/08
    • The invention relates to a process for preparing granisetron, or a pharmaceutically acceptable salt thereof, which comprises: a) cyclisation of a compound of formula (I) in an inert solvent and at a temperature between 0–100° C., in the presence of a strong acid, in order to yield the compound of formula (II); b) methylation of the compound of formula (II), with an alkylating agent, in the presence of a base, in an inert solvent and at a temperature between 0° C.–160° C., and with optional formation of a pharmaceutically acceptable salt. The process of the invention yields a granisetron of high purity, preventing impurities due to demethylation, by carrying out the methylation after rather than before cyclisation and with a higher yield.
    • 本发明涉及一种制备格拉司琼或其药学上可接受的盐的方法,其包括:a)在惰性溶剂中和在0-100℃的温度下,在存在下使式(I)化合物在 的强酸,以产生式(II)的化合物; b)式(II)化合物与烷基化剂在碱的存在下,在惰性溶剂中,在0℃至160℃之间的温度下甲基化,并任选地形成药学上 可接受的盐 本发明的方法产生高纯度的格拉司琼,通过在环化后而不是在环化之前进行甲基化并以较高的产率来防止由于去甲基化引起的杂质。
    • 8. 发明申请
    • Process for preparing a rizatriptan
    • 制备利扎曲坦的方法
    • US20050148778A1
    • 2005-07-07
    • US10509918
    • 2003-08-05
    • Montserrat Armengol AsparoPere Dalmases Barjoan
    • Montserrat Armengol AsparoPere Dalmases Barjoan
    • C07D249/08C07D403/06C07D405/12C07D491/052C07D521/00C07D43/02
    • C07D249/08C07D231/12C07D233/56
    • In particular, rizatriptan or a pharmaceutically acceptable salt thereof, which includes a) Preparation of the diazonium salt of aniline hydrochloride (II); followed by reduction and acidification to give the hydrazine (III); b) reaction in situ of the hydrazine hydrochloride (III) with α-keto-δ-valerolactone, to give the hydrazone (IV); c) Fischer indole reaction of the hydrazone (IV), to give the pyranoindolone (V), optionally followed by a hydrolysis reaction to give (VI); d) Transesterification of (V) or esterification of its hydrolysis product (VI), to give (VII), where R means straight or branched C1-C4 alkyl chain; e) Conversion of the hydroxyl group of (VII) into dimethylamino, to give the indolecarboxylate (VIII), where R has the meaning defined above; f) Saponification of the 2-carboalkoxy group of (VIII) to give indolecarboxylic acid (IX); and g) Decarboxylaton of the indolecarboxylic acid (IX) to give rizatriptan and, eventually, to obtain a pharmaceutically acceptable salt thereof. The invention also relates to synthesis intermediates to obtain rizatriptan.
    • 特别是利扎曲坦或其药学上可接受的盐,其包括a)苯胺盐酸盐(II)的重氮盐的制备; 然后还原和酸化得到肼(III); b)将肼盐酸盐(III)与α-酮-δ-戊内酯原位反应,得到腙(IV); c)腙(IV)的费 - 托吲哚反应,得到吡喃兰多酮(V),任选地随后进行水解反应得到(VI); d)(V)的酯交换或其水解产物(VI)的酯化,得到(VII),其中R表示直链或支链C 1 -C 4烷基链; e)(Ⅶ)的羟基转化为二甲基氨基,得到吲哚羧酸酯(Ⅷ),其中R具有上述定义; f)(VIII)的2-烷氧羰基的皂化得到吲哚羧酸(IX); 和g)吲哚羧酸(IX)的脱羧作用,得到利扎曲坦,最后得到其药学上可接受的盐。 本发明还涉及获得利扎曲普坦的合成中间体。